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Ranolazine is a clinically approved drug for treating cardiac ventricular 
dysrhythmias and angina. Its mechanism(s) of protection is not clearly 
understood but evidence points to blocking the late Na+ current that arises 
during ischemia, blocking mitochondrial complex I activity, or modulating 
mitochondrial metabolism. Here we tested the effect of ranolazine treatment 
before ischemia at the mitochondrial level in intact isolated hearts and in 
mitochondria isolated from hearts at different times of reperfusion. Left 
ventricular (LV) pressure (LVP), coronary flow (CF), and O2 metabolism were 
measured in guinea pig isolated hearts perfused with Krebs-Ringer’s solution; 
mitochondrial (m) O2•−, Ca2+, NADH/FAD (redox state), and cytosolic (c) Ca2+ 
were assessed on-line in the LV free wall by fluorescence spectrophotometry. 
Ranolazine (5 µM), infused for 1 min just before 30 min of global ischemia, 
itself did not change O2•−, cCa2+, mCa2+ or redox state. During late ischemia 
and reperfusion (IR) O2•− emission and m[Ca2+] increased less in the 
ranolazine group vs. the control group. Ranolazine decreased c[Ca2+] only 
during ischemia while NADH and FAD were not different during IR in the 
ranolazine vs. control groups. Throughout reperfusion LVP and CF were 
higher, and ventricular fibrillation was less frequent. Infarct size was smaller 
in the ranolazine group than the control group. Mitochondria isolated from 
ranolazine-treated hearts had mild resistance to permeability transition pore 
(mPTP) opening and less cytochrome c release than control hearts. 
Ranolazine may provide functional protection of the heart during IR injury by 
reducing cCa2+ and mCa2+ loading secondary to its effect to block the late Na+ 
current. Subsequently it indirectly reduces O2•− emission, preserves 
bioenergetics, delays mPTP opening, and restricts loss of cytochrome c, 
thereby reducing necrosis and apoptosis. 




Coronary heart disease remains the leading cause of death 
worldwide [1] despite improvement in its diagnosis and treatment. The 
most effective strategy for treating cardiac injury and limiting infarct 
size is early restoration of coronary blood flow to the ischemic 
myocardium. However, this approach, while essential, is often 
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associated with functional and structural damage during reperfusion 
[2], which is a consequence of the abnormalities that occur during the 
ischemic period [3]. Although the complex mechanisms of ischemia 
and reperfusion (IR) injury are not well understood, many studies 
indicate that both excess reactive oxygen species (ROS) production 
and cytosolic (c) Ca2+ overload play key roles. More recently, 
mitochondrial dysfunction has been proposed to lie at the center of the 
etiology of IR injury because mitochondria act as both sources and 
targets of the injury process. Indeed, mitochondria sustain progressive 
damage during a lengthening of cardiac ischemia [4], and in the 
process become a major source of excess ROS generation [5–7] and 
the initiator of necrosis and apoptosis. Mitochondrial (m) Ca2+ overload 
occurs concurrently with excess ROS production and this leads to a 
subsequent increase in permeability of the inner mitochondrial 
membrane to large solutes, commonly referred to as the mitochondrial 
permeability transition pore (mPTP). An important consequence of 
mPTP opening is expansion of the matrix which, when sufficient, leads 
to rupture of the outer mitochondrial membrane and subsequently 
necrosis [8] and probably apoptosis [9].Thus protecting mitochondria 
against this vicious cycle of perpetual damage by excess mitochondrial 
ROS production and mCa2+ overload associated with IR may preserve 
the structural and functional integrity of mitochondria and other cell 
structures to reduce cardiac injury. 
Ranolazine (RS-43285) [10] is a clinically used anti-anginal drug 
[11–13] that has also been shown to reduce ischemic damage in 
animal models [14–16]. The specific cardioprotective mechanism(s) of 
ranolazine is not well understood especially since, and contrary to 
other antianginal agents, it exerts its effects without significantly 
changing hemodynamic parameters [17]. Several mechanisms have 
been proposed for ranolazine’s cardioprotective effects. One is that 
ranolazine acts by inhibiting fatty acid oxidation during ischemia and 
shifting the metabolism towards glucose oxidation, which is more 
efficient during ischemia due to the limited availability of O2 [18]. 
Another proposal is that ranolazine selectively blocks a ROS-induced 
late sarcolemmal Na+ channel current [19], which may reduce the rise 
in c[Na+] and c[Ca2+] during IR. It has also been suggested that 
ranolazine inhibits complex I of the electron transport chain (ETC) to 
afford protection [20]. Together, these studies clearly show that 
ranolazine protects against cardiac IR injury and suggest that 
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mitochondrial mechanisms may underlie this protection. However, it is 
unknown if ranolazine has a direct or indirect role on mitochondria to 
effect cardiac protection. 
For this study we tested if ranolazine given just before ischemia 
protected mitochondrial function in situ during IR in the intact beating 
heart as well as in isolated mitochondria sequestered at 10 min 
reperfusion. In the intact hearts we assessed mitochondrial redox state 
by noting changes in nicotinamide adenine dinucleotide hydrogen 
(NADH) and flavin adenine dinucleotide (FAD), two indicators of the 
mitochondrial bioenergetic state, as well as increases in mitochondrial 
O2•− emission, c[Ca2+] and m[Ca2+] overload, all of which are markers 
of myocardial injury during IR. We postulated that a decrease in mCa2+ 
loading secondary to a decrease in cCa2+ loading during IR reflects 
inhibition of the late Na+ channel current, whereas an increase in 
mO2•− emission and NADH during ranolazine perfusion indicates a 
possible role for complex I blockade as a mechanism for 
cardioprotection by ranolazine. 
2. Materials and Methods 
2.1. Isolated Heart Preparation 
This investigation conformed to the Guide for the Care and Use 
of Laboratory Animals (US National Institutes of Health Publication No. 
85-23, Revised 1996). The Medical College of Wisconsin Biomedical 
Resources Studies Committee approved this study. Guinea pig hearts 
(n=64) were isolated and prepared as described in detail in our 
previous studies [21–26]. Briefly, animals were anesthetized with 
ketamine (50 mg/kg) and heparin was administered to prevent 
clotting. Following decapitation and thoracotomy, hearts were removed 
and perfused at 55 mmHg via the aortic root with a Krebs Ringer’s 
solution (KR: in mM 138 Na+, 4.5 K+, 1.2 Mg2+, 2.5 Ca2+, 134 Cl−, 15 
HCO3−, 1.2 H2PO4−, 11.5 glucose, 2 pyruvate, 16 mannitol, 0.1 
probenecid, 0.05 EDTA, and 5 U/L insulin) gassed with 3% CO2, 97% 
O2 (pH 7.4) at 37°C. Pyruvate improves performance in isolated 
perfused guinea pig hearts [27,28], and mannitol, a non-metabolized 
sugar, supports the oncotic pressure of the KR solution. Probenecid 
was added to accentuate loading and intracellular retention of 
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fluorescent dyes [29]. A saline-filled balloon catheter attached to a 
transducer was used to measure left ventricular pressure (LVP). 
Coronary flow (CF) was measured using an ultrasonic flowmeter 
(model T106X; Transonic Systems, Ithaca, NY) placed directly into the 
aortic inflow line as previously described [30]. Spontaneous heart rate 
was monitored with bipolar electrodes placed in the right atrial and 
ventricular walls [30]. If ventricular fibrillations, which usually occur 
upon reperfusion, did not convert spontaneously to sinus rhythm after 
30 s, 100 µg lidocaine was injected into the aortic cannula [21]. 
Cardiac O2 consumption (MVO2) was calculated as coronary flow • 
heart weight−1 • (PaO2 − PvO2) • 0.028 µl O2 / ml (37°C) at 760 mmHg. 
2.2. Measurements of Redox State, O2•− and [Ca2+] 
All fluorescence signals were detected at 103 to 105 photons/s. 
FAD fluorescence is derived only from mitochondria; the majority of 
the NADH signal also arises from mitochondria [31–33]. The majority 
of superoxide (O2•−) likely originates from cardiac mitochondria with 
only a small amount derived from non-mitochondrial sources [22]. It is 
known that vascular smooth muscle and endothelial cells generate O2•− 
but their contribution compared to cardiac myocytes is very small. 
After the quenching of cCa2+ signals by MnCl2 the majority of the Ca2+ 
signal is derived from the mitochondrial compartment [34] because of 
its large volume relative to cell volume [35,36]. 
NADH and FAD, c[Ca2+], m[Ca2+], and ROS were measured near 
continuously through the left ventricular (LV) free wall using one of 
four excitation and emission fluorescence spectra [21–26] in different 
subsets of hearts. A trifurcated fiberoptic probe (3.8 mm2/bundle) was 
placed against the LV to excite and record light signals at specific 
wavelengths using spectrophotofluorometers (SLM Instruments Inc, 
Urbana, IL; or Photon Technology International, Birmingham, NJ). 
Light penetration and its fluorescence sensitivity are dependent on the 
light source intensity and wavelength. For Ca2+ the signal is transmural 
but attenuated at the endocardial surface to 20 to 30% of that at the 
epicardial surface [37]. 
In a subset of hearts, as described previously [23,24,38], 10 µM 
dihydroethidium (DHE), a fluorescent probe used to detect the O2•− 
radical [7,39,40], was loaded for 20 min followed by wash out of 
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residual dye; the LV free wall was excited at 540 nm, and light 
emission was recorded at 590 nm. O2•− non-enzymatically converts 
DHE to 2-hydroxyethidium (2-OH-E+) a precursor that appears to be 
rapidly made, is labile, and fluoresces at a slightly shorter wavelength 
than the heme-peroxidase oxidation product ethidium that can 
intercalate with DNA [39,40]. In other hearts NADH autofluorescence 
was assessed at 350 nm excitation and 450 and 390 nm emissions, 
and FAD autofluorescence at 480 nm excitation and 540 nm emission 
[25,33,38,41]. 
Alternatively, other hearts were loaded with 6 µM indo 1 AM for 
30 min to measure total Ca2+ transients using an excitation of 350 nm 
and emissions of 390 and 450 nm. In order to measure m[Ca2+], 
hearts were perfused (before IR) for 15 min with 100 µM MnCl2 to 
quench the cytosolic indo 1 signal [42,43] and then washed out for 15 
min. MnCl2 slightly increased LVP which returned to its original value 
upon washout. The remaining fluorescent signal after quenching 
represented the m[Ca2+] signal [34]. For the c[Ca2+] measurement, 
100 µM MnCl2 was perfused for 15 min by the end of the reperfusion to 
quench the cytosolic indo 1 signal. c[Ca2+] was then calculated from 
the total [Ca2+] after subtracting the mitochondrial component [44]. 
To estimate actual [Ca2+] during the entire protocol, NADH 
autofluorescence was subtracted from the underlying changes in Ca2+ 
fluorescent signals for each group [30,38,45]. Each signal was 
digitized and recorded at 200 Hz on computers for later analyses using 
specifically designed computational programs and commercial software 
(Matlab). pH alone in the range of 6.2–8.0 does not alter the DHE 
fluorescence in our model [23]. Also in preliminary experiments, we 
found that a decrease in pH from 7.4 to 6.5, which may occur during 
ischemia, did not significantly change the indo 1 AM fluorescence 
signal. This excludes the possibility of lactic acidosis buildup during 
ischemia from having significant direct effects on Ca2+, O2•−, and NADH 
signals during ischemia. 
2.3. Protocol 
The study had three groups: IR alone (control, n=24), 5 µM 
ranolazine + IR (ranolazine, n=25), and perfusion without IR or 
ranolazine (time control, n=15). Each group contained subsets of 
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hearts to independently measure and record either NADH plus FAD, 
c[Ca2+], m[Ca2+], or O2•−. Each heart initially underwent a stabilization 
period followed by dye loading and washout of unbound dye to 
specifically measure either c[Ca2+], m[Ca2+] or O2•−. NADH and FAD 
autofluorescence were assessed simultaneously [30,38,45,46] using a 
protocol similar to that of the indo 1 fluorescence dye-loaded hearts. 
All hearts undergoing IR were perfused only briefly (1 min) with 
ranolazine, or no treatment (vehicle), immediately before the onset of 
30 min of no flow global ischemia. This protocol assured that hearts 
were treated with the drug only briefly before ischemia and that the 
drug was present in the heart during the ischemic period but not on 
reperfusion. This treatment effect is not a classical preconditioning 
protocol in which the drug is washed out completely before ischemia. 
Ranolazine perfusion alone caused a small but significant depression of 
LVP and a significant increase in CF. We have shown previously that 
after a one min drug perfusion before ischemia a given drug is no 
longer present at the initiation of reperfusion [38]; thus, we expect 
ranolazine is not present on reperfusion. 
Ranolazine itself did not alter the fluorescence characteristics or 
spectra of any dye. Therefore, any observed changes in fluorescent 
spectra were most likely attributed only to the effects induced by IR. 
After ischemia each heart was reperfused with KR solution without 
ranolazine for 120 min. At the end of each experiment hearts were 
removed and atria were discarded; ventricles were cut into thin 
transverse sections (4–5) of approximately 3 mm each and incubated 
in buffered 0.1% 2,3,5-triphenyltetrazolium chloride (TTC) to stain 
viable tissue from necrotic tissue for estimating infarct size using a 
cumulative planimetry technique [47]. 
2.4. Assessment of Mitochondrial Membrane Integrity 
In another set of experiments, isolated hearts (n=6) were 
treated as described above ± ranolazine treatment followed by 30 min 
ischemia, but subjected to only 10 min reperfusion. Hearts were then 
immediately removed from the perfusion apparatus and mitochondria 
were isolated as described by us previously [48–50]. This time point 
(10 min reperfusion) was chosen because mitochondria may be more 
susceptible to mPTP opening due to the disturbance in Ca2+ 
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homeostasis, the increase in ROS production, and increase in pH, 
without loss of non-viable mitochondria. 
In brief, ventricles were excised, placed in an isolation buffer 
(buffer A) (200 mM mannitol, 50 mM sucrose, 5 mM KH2PO4, 5 mM 
MOPS, 1 mM EGTA, and 0.1% BSA, with pH adjusted to 7.15 with 
KOH), and minced into 1-mm3 pieces. The suspension was 
homogenized for 15 s in 2.5 ml isolation buffer containing 5 U/ml 
protease (Bacillus licheniformis) and for another 15 s after adding 17 
ml isolation buffer. The suspension was centrifuged at 8,000 g for 10 
min, the pellet was re-suspended in 25 ml of isolation buffer and 
centrifuged at 750 g for 10 min, the supernatant was centrifuged again 
at 8,000 g for 10 min, and the final pellet was suspended in 0.5 ml of 
isolation buffer and kept on ice. Protein content was determined by the 
Bradford method [51]. All isolation procedures were conducted at 4°C 
and isolated mitochondrial experiments were conducted at room 
temperature (25°C). Before initiating the mitochondrial experiments, 
respiratory control index (state 3/state 4 respiration, RCI) was 
determined to be 11.6±0.3 for the complex I substrate pyruvate; this 
demonstrated a strong coupling between mitochondrial respiration and 
phosphorylation in guinea pig heart isolated mitochondria. 
2.4.1. Mitochondrial Membrane Potential and mPTP Opening  
Mitochondria were suspended in respiration buffer (buffer B) 
(130 mM KCl, 5 mM K2HPO4, 20 mM MOPS, 2.5 mM EGTA, 1 µM 
Na4P2O7, 10 mM pyruvate, and 0.1% BSA, with pH adjusted to 7.15 
with KOH) inside a cuvette-based spectrophotometer (model QM-8, 
Photon Technology International, Birmingham, NJ). Membrane 
potential (ΔΨm) was monitored in the presence of the fluorescent dye 
rhodamine 123 (50 nM) using excitation and emission wavelengths of 
503 and 527 nm, respectively [49,50]. After a 2 min stabilization 
period, pulses of CaCl2 (25 µM) were given every min until ΔΨm 
completely depolarized indicating mPTP opening. In some 
experiments, cyclosporine A (0.5 µM), which inhibits mPTP opening, 
was added to the mitochondrial suspension at the beginning of the 
protocol to confirm mPTP opening by excess added CaCl2. In addition 
to the pulse method we used the slow infusion approach of CaCl2 (25 
µM/min) into the mitochondrial suspension. The responses of 
mitochondria were not different between the two approaches. 
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2.4.2 Mitochondrial Ca2+ Retention and mPTP Opening  
In addition to ΔΨm for assessing mitochondrial membrane 
integrity, m[Ca2+] was measured as described recently [52], while 
mitochondria were challenged with extra-matrix pulses of CaCl2 (25 
µM). In brief, isolated guinea pig heart mitochondria were incubated 
with 1 µM indo 1 AM in the same isolation buffer (buffer A) described 
above for 20 min at room temperature with continuous stirring. The 
suspension was then diluted with isolation buffer and centrifuged at 
8,000 g for 10 min to remove excess dye. Mitochondria were then re-
suspended in isolation buffer and stored on ice. The protein content 
was determined by the Bradford method. Assays were carried out with 
mitochondria suspended in respiration buffer (buffer B) inside the 
cuvette-based spectrophotometer at room temperature (25°C) with 
the light beam filtered at an excitation wavelength of 350 nm and 
emission wavelengths of 390 nm and 450 nm. 
2.5. Cytochrome c Levels in Cytosolic and Mitochondrial 
Fractions 
Mitochondria were isolated as described above with minor 
modifications to separate the cytosolic from the mitochondrial fractions 
by differential centrifugation [53]. All isolation procedures were 
conducted at 4°C. Briefly, heart tissues were minced and homogenized 
as described above. However, after the first spin the supernatant was 
further centrifuged at 14,000 g for 30 min to obtain pure cytosolic 
fractions. The pellet from the first spin was resuspended in isolation 
buffer and centrifuged at 750 g for 10 min. The supernatant was 
collected and centrifuged again at 8,000 g for 10 min, and the final 
pellet was resuspended in isolation buffer and represented the 
mitochondrial fraction. Cytosolic and mitochondrial fractions were 
stored at −80°C until use. Protein content was determined by the 
Bradford method [51] followed by standard Western blotting 
procedures. 
Cytosolic and mitochondrial samples were boiled in Laemmli 
buffer followed by resolving on SDS-PAGE as described by Laemmli 
[54] and transferred onto a polyvinylidene difluoride (PVDF) 
membrane using the Transblot system (Bio-Rad, Richmond, CA). 
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Membranes were blocked in Tween-20 Tris-buffered saline (TTBS) 
buffer (25 mM TrisCl pH 7.5, 150 mM NaCl and 0.1% Tween 20) 
containing 5% milk for 1 h, and then incubated with cytochrome c 
primary antibody (1:1000 dilution, Invitrogen, CA) overnight at 4°C. 
After washing 3 times with TTBS the next day, the membranes were 
incubated in an appropriate secondary antibody conjugated to 
horseradish peroxidase and then immersed in an enhanced 
chemiluminescence detection solution (ECL plus from GE Healthcare, 
Buckinghamshire, UK) and exposed to X-ray film for autoradiography. 
After stripping cytochrome c antibody, protein loading of cytosolic 
fractions was confirmed using an antibody against β–actin (1:200, 
Santa Cruz, CA) and purity was confirmed by checking for 
mitochondrial contamination using an antibody against voltage 
dependent anion channel (VDAC) (1:1000, Cell Signaling, Danvers, 
MA). 
2.6. Statistical Analysis 
For the intact heart studies, measurements for each group were 
compared at baseline, during the brief treatment with or without 
ranolazine before ischemia, at 15 and the last 5 (25–30) min of 
ischemia, and at the first 5 (1–5), 30, 60, and 120 min reperfusion. All 
data are expressed as mean ± SEM. Values for NADH, FAD and O2•− 
are expressed in arbitrary fluorescence units (afu), and c[Ca2+] and 
m[Ca2+] are given in nM after subtracting background 
autofluorescence [55]. Between groups and within group comparisons 
were performed by two-way analysis of variance to determine 
significance (SigmaPlot 11.0, Systat Software Inc, San Jose, CA). If F 
values were significant (P < 0.05), post hoc comparisons of means 
tests (Student-Newman-Keuls) were used to compare the groups 
within each subset. In mitochondrial studies, statistical analysis was 
performed using one-way analysis of variance. All data are expressed 
as mean ± SEM. Differences between means were considered 
significant when P < 0.05 (two-tailed). 
3. Results 
Baseline values were not different among groups for all 
measurements in intact heart studies. To assess the role of 
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mitochondria in overall cardiac functional and metabolic recovery by 
ranolazine, mitochondrial bioenergetics, i.e., NADH and FAD, DHE 
(indicative of mitochondrial O2•− emission), and indo 1 fluorescence 
(indicative of [Ca2+]) were monitored in different subsets of hearts. 
Figures 1A and 1B show, respectively, timeline changes in NADH 
(baseline value 40±0.2 afu) and FAD (baseline value 80±0.3 afu), 
indicators of mitochondrial redox state, during the 1 min period of 
ranolazine or no treatment (arrow), during ischemia, and throughout 
reperfusion. An increase in NADH and a decrease in FAD indicate a 
more reduced mitochondrial redox state [38,45]. Brief perfusion of 
ranolazine did not change NADH or FAD. Ischemia caused an abrupt, 
significant increase in NADH autofluorescence and a reciprocal 
decrease in FAD autofluorescence in both groups. On reperfusion, 
NADH and FAD autofluorescence signals returned to baseline values in 
the control and ranolazine treated hearts without a significant 
difference between the two groups. 
 
Figure 1 Changes in NADH autofluorescence (A) and FAD autofluorescence (B) 
during 1 min treatment with or without ranolazine, and during and after 30 min of no 
flow global ischemia. Arrow indicates 1 min ranolazine (n=6) or control (n=6) 
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perfusion immediately before ischemia. *P < 0.05, 1 min perfusion before ischemia, 
during ischemia and reperfusion vs. baseline values; #P < 0.05 ranolazine vs. control. 
Whereas NADH and FAD are markers of the mitochondrial redox 
state during IR injury, O2•− emission, c[Ca2+], and m[Ca2+] overload 
are key effectors in the mechanism of cellular injury following IR. 
Figure 2A shows timeline changes in O2•− during the 1 min period of 
ranolazine or no treatment (arrow), during ischemia, and throughout 
reperfusion. Ranolazine perfusion, per se, did not alter O2•− emission. 
Ischemia initially caused a marked increase in O2•− in both groups; by 
25 min ischemia O2•− increased more in the control IR group and 
remained higher during reperfusion than in the ranolazine treated 
group. Figure 2B shows timeline changes in average m[Ca2+] (baseline 
value 151±2 nM) during the brief perfusion of ranolazine or no 
treatment (arrow), during ischemia, and throughout reperfusion. 
Ranolazine perfusion, per se, did not change m[Ca2+]. Ischemia 
caused m[Ca2+] to increase in both groups but more so in the control 
group (445±45 nM) than in the ranolazine group (308±25 nM) at 15 
min ischemia. At 1 min reperfusion, m[Ca2+] increased in the control 
group while it did not change in the ranolazine group. During the 
remainder of reperfusion, m[Ca2+] continued to decrease towards 
baseline in both groups, but it was significantly less in the ranolazine 
treated group than in the untreated control group. 
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Figure 2 Changes in DHE fluorescence (indicative of superoxide, O2•−) (A) and indo 
1 fluorescence (indicative of m[Ca2+] (B) during 1 min treatment with or without 
ranolazine, and during and after 30 min of no flow global ischemia. Arrow indicates 1 
min ranolazine (n=8 for superoxide; n=6 for m[Ca2+]) or control (n=5 for superoxide; 
n=6 for m[Ca2+]) perfusion immediately before ischemia. *P < 0.05, 1 min perfusion 
before ischemia, during ischemia and reperfusion vs. baseline values; #P < 0.05 
ranolazine vs. control. 
Increases in m[Ca2+] during IR insult follow increases in c[Ca2+]. 
Figures 3A and 3B show timeline changes in systolic (baseline value 
550±4 nM) and diastolic (baseline value 250±3 nM) [Ca2+] before, 
during, and after ischemia. Note that after 5–8 min ischemia hearts 
cease to beat and so there is no difference between systolic and 
diastolic [Ca2+]. Systolic [Ca2+] decreased once ischemia was initiated 
but then c[Ca2+] increased gradually during ischemia in both groups, 
but more so in the control group (410±36 nM) than in the ranolazine 
group (315±38 nM) at 15 min ischemia. At the beginning of 
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reperfusion (1 min), systolic and diastolic [Ca2+] increased significantly 
in the control group (823±70 nM, 492±46 nM, respectively) compared 
to the ranolazine group (631±25 nM, 337±16 nM, respectively) and 
then decreased and remained similar in both groups throughout 
reperfusion. 
 
Figure 3 Changes in systolic (A) and diastolic (B) indo 1 fluorescence (indicative of 
systolic and diastolic [Ca2+], respectively) during 1 min treatment with or without 
ranolazine, and during and after 30 min of no flow global ischemia. During early 
ischemia Ca2+ transients continue to occur; once these transients cease, systolic and 
diastolic Ca2+ are the same. Arrow indicates 1 min ranolazine (n=5) or control (n=7) 
perfusion immediately before ischemia. *P < 0.05, 1 min perfusion before ischemia, 
during ischemia and reperfusion vs. baseline values; #P < 0.05 ranolazine vs. control. 
Insets show systolic (A) and diastolic (B) [Ca2+] at 30 min ischemia (white columns) 
and at 1 min reperfusion (dark columns). *P < 0.05 [Ca2+] at 1 min reperfusion vs. 30 
min ischemia. #P < 0.05 ranolazine vs. control. 
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Figures 4A and 4B show timeline changes in systolic minus 
diastolic LVP (developed LVP, baseline value 90±2 mmHg) and 
diastolic LVP (diaLVP, baseline value set to 0 mmHg), respectively. 
Ranolazine by itself caused a small decrease in developed LVP. Upon 
reperfusion, ranolazine-treated hearts exhibited higher developed LVP 
(67±9 mmHg) and lower diastolic LVP (6±2 mmHg) vs. control hearts 
(developed LVP 25±8 mmHg, diastolic LVP 20±4 mmHg). Throughout 
reperfusion, developed LVP remained significantly lower in control 
hearts than in ranolazine-treated hearts. 
 
Figure 4 Changes in developed left ventricular pressure (A) and diastolic left 
ventricular pressure (B) during 1 min treatment with or without ranolazine, and during 
and after 30 min of no flow global ischemia. Arrow indicates 1 min ranolazine (n=14) 
or control (n=11) perfusion immediately before ischemia. *P < 0.05, 1 min perfusion 
before ischemia, during ischemia and reperfusion vs. baseline values; #P < 0.05 
ranolazine vs. control. 
Figure 5A shows timeline changes in coronary flow (baseline 
value 9±0.1 ml/g/min) before, during, and after ischemia in both 
groups. Ranolazine perfusion (arrow) caused a small increase in 
coronary flow. During reperfusion coronary flow decreased in both 
groups but remained significantly higher in ranolazine-treated hearts 
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throughout reperfusion, i.e. 7.8±0.5 ml/g/min vs. 5.5±0.3 ml/g/min in 
control hearts at 120 min reperfusion. In the time control experiments 
(no ischemia), all measured variables at 120 min were not significantly 
different from baseline values (data not shown) [38]. This suggests 
stability of the heart in this perfusion model. 
 
Figure 5 Changes in coronary flow (A) during 1 min treatment with or without 
ranolazine, and during and after 30 min of no flow global ischemia. Arrow indicates 1 
min ranolazine (n=14) or control (n=11) perfusion immediately before ischemia. Panel 
B shows infarct size as a percentage of total ventricular weight measured after 120 
min reperfusion for ranolazine (n=14) and control groups (n=11). *P < 0.05, 1 min 
perfusion before ischemia, during ischemia and reperfusion vs. baseline values; #P < 
0.05 ranolazine vs. control. 
Table 1 shows improved cardiac contractility, relaxation, and O2 
consumption in ranolazine-treated hearts vs. control hearts during the 
reperfusion period. Heart rate was not different between the two 
groups throughout the reperfusion. Ranolazine treatment reduced the 
incidence of ventricular fibrillation which occurred during the first 10 
min of reperfusion compared to IR only control hearts (i.e. 17% vs. 
100%). 
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Table 1 Changes in Heart rate, O2 Consumption and cardiac contractility and 
relaxation at baseline, during 1 min of treatment with ranolazine or KR, and at 
selected intervals during reperfusion. 
Figure 5B shows ventricular infarct size as a percentage of total 
ventricular weight (area at risk) for both groups after 120 min 
reperfusion. Infarct size was larger in control hearts (39±3%) than in 
ranolazine-treated hearts (21±2%). 
Figure 6 shows representative traces for ΔΨm (Panel A) and 
m[Ca2+] (Panel B) measured during Ca2+ pulse challenges in 
mitochondria isolated from control (line 1, 3) and ranolazine-treated 
(line 2, 4) hearts. Mitochondria were exposed to pulses of 25 µM CaCl2 
injected every min into the mitochondrial suspension to instigate 
pathologic Ca2+ overload. Mitochondria isolated from control IR hearts 
exhibited earlier mitochondrial depolarization and lower Ca2+ retention 
capacity than mitochondria isolated from ranolazine-treated hearts. 
Lines 3 and 4 are similar to lines 1 and 2 except that cyclosporine A 
(CSA, 0.5 µM) was added to the suspension to prevent mPTP opening. 
ΔΨm did not change with added CaCl2 pulses in the presence of CSA, 
which indicates that the mitochondrial depolarization observed in lines 
1 and 2 is due to opening of mPTP. Figure 6C summarizes the number 
of pulses of 25 µM CaCl2 needed to reach maximal Ca2+ retention 
capacity and to initiate mitochondrial depolarization. IR only hearts 
required fewer pulses (3.8±0.2) to induce ΔΨm collapse compared to 
ranolazine-treated hearts (4.8±0.7) suggesting a relative delay in 
mPTP opening. Inset in Figure 6A shows membrane potential 
measurement in freshly isolated mitochondria from hearts that were 
neither subjected to IR nor perfused with KR as time control. The data 
were obtained from mitochondria that were challenged with constant 
infusion of 25 µM/min CaCl2. Ranolazine, cyclosporine A, or vehicle 
(control) was added to the mitochondrial suspension at the beginning 
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of the run. Ranolazine did not directly delay mPTP opening as did 
cyclosporine A and it was not different from vehicle (determined by the 
depolarization in ΔΨm). 
 
Figure 6 Representative traces of rhodamine 123 fluorescence (indicative of 
membrane potential, ΔΨm) (A) and indo 1 fluorescence (indicative of m[Ca2+]) (B) in 
mitochondria isolated from IR only hearts (traces 1, 3; n=3) and ranolazine + IR 
hearts (traces 2, 4; n=3). Mitochondria (0.5 mg/ml) were suspended in KCl-based 
experimental buffer containing 10 mM pyruvate. In traces 3 and 4, the mitochondrial 
suspension also contained 0.5 µM cyclosporine A to prevent mPTP opening. The arrows 
indicate when pulses of 25 µM of CaCl2 were added to the mitochondrial suspension. 
Panel C shows a summary of the number of CaCl2 pulses needed to reach maximal 
Ca2+ retention capacity and to initiate ΔΨm depolarization. #P < 0.05 ranolazine vs. 
control. Inset in panel A represents traces of rhodamine 123 fluorescence (membrane 
potential, ΔΨm) with 25 µM/min of CaCl2 constantly infused in the mitochondrial 
suspension with the addition of either ranolazine, cyclosporine A or vehicle as control. 
Arrow in the inset indicates when ranolazine, cyclosporine A, or vehicle was added. 
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Figure 7 shows mitochondrial cytochrome c release assayed in 
cytosolic fractions obtained from the time control, IR only, and 
ranolazine + IR groups (Panel A). Compared to the time-matched 
controls, the control treated hearts at 30 min of reperfusion (IR30) 
and 60 min of reperfusion (IR60) displayed a higher amount of 
cytochrome c in the cytosol. When hearts were treated briefly with 
ranolazine before ischemia, the amount of cytochrome c released into 
the cytosol was markedly abated. Protein levels of β–actin were similar 
among groups, indicating equal protein loading of the cytosolic 
fraction. The lack of expression of VDAC in the cytosol demonstrated 
that the cytosolic fractions were not contaminated by the 
mitochondrial fractions. Panel B summarizes the levels of cytochrome c 
band densities in the cytosol following IR. Cytochrome c release was 
higher after 60 min reperfusion than at 30 min reperfusion. Ranolazine 
treatment before ischemia attenuated cytochrome c release at 30 min 
and 60 min reperfusion, but there was no significant difference in 
cytochrome c release between these two time points. 
 
Figure 7 Representative cytochrome c measurements (A) using Western blotting in 
cytosolic and mitochondrial fractions. Data are summarized in panel B. Abbreviations 
are: RAN, hearts treated with ranolazine only without ischemia; CON, hearts not 
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treated with ranolazine and not exposed to ischemia; IR30, hearts exposed to 30 min 
ischemia and 30 min reperfusion without treatment with ranolazine; RAN+IR30, hearts 
treated with ranolazine followed by 30 min ischemia and 30 min reperfusion; IR60, 
hearts exposed to 30 min ischemia followed by 60 min reperfusion without treatment 
with ranolazine; RAN+IR60, hearts treated with ranolazine followed by 30 min 
ischemia and 60 min reperfusion. *P < 0.05 ischemia groups vs. no ischemia groups. 
#P < 0.05 RAN+IR30 or RAN+IR60 vs. IR30 or IR60.  
4. Discussion 
Our results indicate clearly that ranolazine, when present during 
ischemia, protects isolated hearts against IR injury as shown by the 
higher developed LVP and lower diastolic LVP on reperfusion, by the 
smaller infarct size, and by the decreased incidence of dysrhythmias. 
This improvement in cardiac function was associated with less O2•− 
production and reduced cCa2+ and mCa2+ overload without an effect on 
redox state (NADH, FAD). Ranolazine treatment improved coronary 
flow on reperfusion suggesting less injury to vascular and endothelial 
cells than to heart muscle cells. During 1 min perfusion before IR, 
ranolazine did not change O2•−, cCa2+, mCa2+, NADH, or FAD. In 
addition, mitochondria isolated from ranolazine-treated hearts showed 
a small resistance to collapse of ΔΨm due to mCa2+ overload as 
evidenced by a delay in mPTP opening and less cytochrome c release. 
Although ranolazine treatment improved LVP and coronary flow on 
reperfusion, it is unlikely that the higher flow was responsible for the 
higher LVP because artificially increasing flow after ischemia does not 
improve contractility (unpublished data) suggesting there is more 
injury to contractile cells than to vascular or endothelial cells. 
Mitochondria play a crucial role in IR injury and hence are 
promising targets for novel antiischemic therapies. The importance of 
mitochondria as both targets and mediators of IR is becoming 
increasingly recognized [4]. It is often demonstrated that excess 
mitochondrial ROS and mCa2+ overload are the two major factors that 
are intertwined in the pathology of IR injury. But how they are 
correlated, or how they influence each other, is a subject of intense 
debate. As noted in a review article by Brookes et al. [56], excess 
m[Ca2+] can cause an increase in ROS by different mechanisms such 
as by stimulation of citric acid cycle and oxidative phosphorylation to 
increase electron leak, by enhancing NO• generation which blocks 
complex IV and causes electron leak from complex III, and by 
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enhancing cytochrome c dislocation. On the other hand, ROS was 
shown to enhance Ca2+ release from the sarcoplasmic reticulum [57]. 
These events could underlie our findings for Ca2+-induced ROS 
production in IR injury and the reduction of both after treatment with 
ranolazine. An increase in m[Ca2+] [38,58] is caused by the increase in 
c[Ca2+] as shown in our study (Figure 3) and reported by others 
[21,59,60]. The increase in c[Ca2+] and m[Ca2+] may result from an 
increase in c[Na+] and activation of the Na+/Ca2+ exchange. The 
increase in c[Na+] results from failed Na+/K+ ATPase pump activity 
during ischemia and early reperfusion, coupled with an increased pH 
gradient between the intracellular and extracellular spaces and the 
activation of the relatively quiescent Na+/H+ exchanger [61]. 
However, increased c[Na+] may also arise in part from 
activation of the late Na+ current by some toxic ischemic metabolites 
[62,63] and by ROS that are generated during reperfusion [64]. Thus 
ranolazine, as an inhibitor of the late Na+ current, could reduce c[Na+] 
during ischemia and subsequently reduce c[Ca2+]. Song et al. [65] 
reported that ranolazine attenuated H2O2-induced intracellular Na+ and 
Ca2+ overload in rabbit isolated ventricular myocytes. Our current 
study supports and extends the study by Song et al. by demonstrating 
that ranolazine not only causes a decrease in c[Ca2+] (Figure 3), but 
also more importantly, resulted in a decrease in m[Ca2+] during 
ischemia in intact beating hearts (Figure 2B). Although m[Ca2+] also 
increased during late ischemia in ranolazine-treated hearts, 
mitochondria from these hearts were better able to rapidly expel the 
excess Ca2+ and lower their Ca2+ content immediately on reperfusion 
than the control IR only hearts. This is highly relevant since the most 
damaging Ca2+ influx appears to occur during early reperfusion [66]. 
Mitochondria maintain a delicate balance between ROS 
generation and ROS scavenging; this difference is called ROS 
emission. However, under pathological conditions such as in cardiac 
IR, the balance that keeps ROS to a minimum is altered due to the 
increase in ROS generation coupled with a decrease in ROS scavenging 
capability. The decrease in ROS scavenging capacity during ischemia is 
likely a result of multiple factors such as the loss of reducing 
equivalents (NADH, FADH2) which are necessary to recharge the ROS 
scavenging capacity of glutathione, thioredoxin, peroxiredoxins and 
other scavenging systems [67], or due to release of cytochrome c 
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(also a ROS scavenger) in the cytosol as a result of mPTP opening, or 
transient partial permeabilization of the outer mitochondrial membrane 
[67]. It is unlikely that ranolazine reduces ROS during ischemia by 
providing more NADH for the glutathione system since our results 
show that ranolazine did not further increase mitochondrial NADH 
during IR (Figure 1A) compared to IR controls. 
On the other hand, ranolazine treatment reduced the release of 
cytochrome c into the cytosol (Figure 7). Cytochrome c can accept or 
donate an electron depending on the redox state of its heme (Fe). 
Thus it can scavenge O2•− through its capacity to be reduced 
alternatively by the transfer of electrons from O2•−, thereby reducing 
ROS emission [67,68]. It is therefore possible that by preserving the 
scavenging capacity of cytochrome c, and/or by increasing the 
efficiency of electron transfer through the ETC, ranolazine treatment 
reduced ROS especially during reperfusion. 
The increase in mitochondrial O2•− generation arises primarily 
from an impaired electron flux via the ETC due to the low 
mitochondrial O2 concentration, and O2•− production primarily occurs 
from mitochondrial complexes I and III [6,56] with complex III playing 
a central role in this process [69]. In a previous study [38] using a 
similar experimental protocol, we showed that blocking complex I of 
the ETC with amobarbital, a reversible complex I blocker, decreased 
electron flow to complex III and subsequently reduced ROS generation 
and protected mitochondria against ischemic injury. Like amobarbital, 
ranolazine is reported to block complex I [20], albeit as a weaker 
inhibitor compared to amobarbital or rotenone, especially in 
energetically coupled mitochondria. However, in uncoupled 
mitochondria, ranolazine had a greater effect to inhibit complex I [20]. 
It was suggested that this occurs because the lower membrane 
potential in uncoupled mitochondria, with a more acidic environment, 
favors greater protonation and uptake of ranolazine, or that it is only 
the charged form of ranolazine that is inhibitory [20]. It is important to 
note that our experiments showed no evidence of a direct effect of 
ranolazine to block complex I in the isolated heart or in isolated 
mitochondrial studies. 
We observed similar levels of NADH during IR in ranolazine-
treated and control hearts which may seem to be in contradiction with 
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our previous studies [38,45,70] that show higher NADH levels are 
associated with better cardiac recovery. This could result from the fact 
that ranolazine has been reported to stimulate glucose oxidation in 
ischemic, and reperfused ischemic hearts [18] by indirectly increasing 
the amount of the active dephosphorylated form of the pyruvate 
dehydrogenase complex [71], which may lead to more usage of the 
available NADH. 
In conclusion, ranolazine protected mitochondria against IR as 
shown by the lesser O2•− production and reduced cCa2+ and mCa2+ 
overload. This was associated with a small delay in mPTP opening but 
there was no strong evidence for a direct effect of ranolazine 
treatment on a component of the pore. We observed in freshly isolated 
mitochondria (inset in Figure 6A) that ranolazine did not directly delay 
mPTP opening-induced membrane potential depolarization as does 
cyclosporine A. Moreover, in companion studies, we found that 
ranolazine preserved the mitochondrial supercomplexes in part by 
restoring cardiolipin and so preserved electron flux in mitochondrial 
Fe-S clusters during IR [72–74].Yet, it is still undetermined if these 
results are due to direct or indirect effect of ranolazine on 
mitochondria. These observations along with our other preliminary 
data (not shown), and importantly, the results reported in this current 
study all imply an indirect mechanism for ranolazine to protect 
cardiomyocyte mitochondria. Although ranolazine-treated hearts 
showed a slightly higher resistance to mPTP opening and reduced 
cytochrome c release, we attribute these findings to indirect 
preservation of mitochondria. Overall, our results indicate that 
ranolazine may confer protection against IR in our model by reducing 
cCa2+ and mCa2+ loading and ROS, possibly secondary to blocking the 
late Na+ channel current. Even though we did not observe any direct 
evidence of a mitochondrial effect of ranolazine, it clearly contributes 
to mitochondrial protection via its overall cardioprotective effect. 
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